- Home
- BANC vs KNSA Comparison
BANC vs KNSA Comparison
Compare BANC & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANC
- KNSA
- Stock Information
- Founded
- BANC 1941
- KNSA 2015
- Country
- BANC United States
- KNSA United Kingdom
- Employees
- BANC N/A
- KNSA N/A
- Industry
- BANC Major Banks
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- BANC Finance
- KNSA Health Care
- Exchange
- BANC Nasdaq
- KNSA Nasdaq
- Market Cap
- BANC 2.2B
- KNSA 2.0B
- IPO Year
- BANC N/A
- KNSA 2018
- Fundamental
- Price
- BANC $13.75
- KNSA $26.03
- Analyst Decision
- BANC Buy
- KNSA Strong Buy
- Analyst Count
- BANC 12
- KNSA 6
- Target Price
- BANC $17.25
- KNSA $38.00
- AVG Volume (30 Days)
- BANC 2.7M
- KNSA 677.6K
- Earning Date
- BANC 04-23-2025
- KNSA 04-29-2025
- Dividend Yield
- BANC 2.91%
- KNSA N/A
- EPS Growth
- BANC N/A
- KNSA N/A
- EPS
- BANC 0.65
- KNSA N/A
- Revenue
- BANC $964,190,000.00
- KNSA $481,166,000.00
- Revenue This Year
- BANC $12.25
- KNSA $37.21
- Revenue Next Year
- BANC $9.00
- KNSA $1.53
- P/E Ratio
- BANC $21.08
- KNSA N/A
- Revenue Growth
- BANC 415.34
- KNSA 59.45
- 52 Week Low
- BANC $11.52
- KNSA $17.38
- 52 Week High
- BANC $18.08
- KNSA $28.56
- Technical
- Relative Strength Index (RSI)
- BANC 53.65
- KNSA 63.21
- Support Level
- BANC $12.98
- KNSA $25.97
- Resistance Level
- BANC $13.98
- KNSA $28.56
- Average True Range (ATR)
- BANC 0.41
- KNSA 1.24
- MACD
- BANC 0.10
- KNSA 0.36
- Stochastic Oscillator
- BANC 56.20
- KNSA 71.70
About BANC Banc of California Inc.
Banc of California Inc is a financial holding company. It offers banking and financial services. Its services include banking services, lending services, and private banking services. Its deposit and banking product and service offerings include checking, savings, money market, certificates of deposit, and retirement accounts. Lending activities are focused on providing financing to California's diverse private businesses, entrepreneurs, and communities, and loans are often secured by California commercial and residential real estate. The company has one reportable segment named Commercial banking.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.